Home・Lista de Ações・Intellia Therapeutics Inc

Intellia Therapeutics Inc

Fechado

SetorSaúde

12.83 3.05

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.81

Máximo

12.98

Indicadores-chave
By Trading Economics
Rendimento	-107M -203M
Vendas	-7.4M 7.7M
EPS	-0.8
Margem de lucro	-2,648.714
Funcionários	377
EBITDA	-11M -105M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+62.77% upside

Dividendos
By Acuity
Próximos Ganhos	4 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	189M 1.7B
Abertura anterior	9.78
Fecho anterior	12.83

Sentimento de Notícias

By Acuity

60%

40%

287 / 340 Ranking em Healthcare

Intellia Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de ago. de 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

20 de ago. de 2026, 19:26 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting declines in the biotechnology sector and the Russell 2000 Index amid challenging market conditions.

19 de ago. de 2026, 20:02 UTC

Correlated Moves

Intellia Therapeutics shares are higher today, reflecting strong investor interest and positive sentiment in the genomics sector, aided by gains in ARK and CRSP.

17 de ago. de 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher, continuing an upward trend since Friday amid positive sentiment in the biotechnology sector and rising long-term Treasury yields.

14 de ago. de 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc. shares rose in after-market trading, reflecting positive market dynamics. The stock remains above its 20-day moving average.

11 de ago. de 2026, 19:33 UTC

News

Intellia Therapeutics shares are lower after Brookline Capital Markets revised Q2 2026 earnings estimates to a loss of -$0.80 per share.

10 de ago. de 2026, 19:46 UTC

News

Intellia Therapeutics shares rise as analysts boost price targets, with Wedbush raising its target to $17.00 while maintaining a “neutral” rating.

7 de ago. de 2026, 19:26 UTC

News

Correlated Moves

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

6 de ago. de 2026, 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

4 de ago. de 2026, 19:36 UTC

Correlated Moves

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

3 de ago. de 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

31 de jul. de 2026, 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30 de jul. de 2026, 17:57 UTC

Correlated Moves

News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29 de jul. de 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28 de jul. de 2026, 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

27 de jul. de 2026, 23:46 UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

25 de jul. de 2026, 00:02 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

24 de jul. de 2026, 13:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

23 de jul. de 2026, 19:16 UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

22 de jul. de 2026, 23:56 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

21 de jul. de 2026, 22:46 UTC

Intellia Therapeutics Inc shares are lower in after-market trading amid a lack of specific company news. The stock remains below its 20-day moving average.

20 de jul. de 2026, 23:41 UTC

Correlated Moves

Intellia Therapeutics shares are higher in after-market trading, reflecting a positive shift amid broader market trends and correlated gains in Beam Therapeutics.

Comparação entre Pares

Variação de preço

Intellia Therapeutics Inc Previsão

Preço-alvo

By TipRanks

62.77% parte superior

Previsão para 12 meses

Média 20.9 USD 62.77%

Máximo 49 USD

Mínimo 9 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Intellia Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Intellia Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

287 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.